Pyxis Current Deferred Revenue vs Cash And Short Term Investments Analysis

PYXS Stock

USD 1.83 0.06 3.39%

Pyxis Oncology financial indicator trend analysis is much more than just breaking down Pyxis Oncology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pyxis Oncology is a good investment. Please check the relationship between Pyxis Oncology Current Deferred Revenue and its Cash And Short Term Investments accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pyxis Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy Pyxis Stock please use our How to Invest in Pyxis Oncology guide.

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pyxis Oncology Current Deferred Revenue account and Cash And Short Term Investments. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Pyxis Oncology's Current Deferred Revenue and Cash And Short Term Investments is 0.84. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Pyxis Oncology, assuming nothing else is changed. The correlation between historical values of Pyxis Oncology's Current Deferred Revenue and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Pyxis Oncology are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Current Deferred Revenue i.e., Pyxis Oncology's Current Deferred Revenue and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Pyxis Oncology balance sheet. This account contains Pyxis Oncology investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Pyxis Oncology fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Pyxis Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pyxis Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pyxis Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy Pyxis Stock please use our How to Invest in Pyxis Oncology guide.Selling General Administrative is likely to drop to about 20.7 M in 2024. Issuance Of Capital Stock is likely to drop to about 5.8 M in 2024

	2021	2022	2023	2024 (projected)
Interest Income	23K	2.8M	6.9M	7.3M
Net Interest Income	23K	2.8M	6.9M	7.3M

Interest Income Net Interest Income

Pyxis Oncology fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.64	0.78	0.91	1.0	0.99	0.66	0.91	-0.73	-0.77	0.97	0.8	0.59	0.63	0.99	0.13	-0.82	0.64	0.92	0.71	0.56	1.0	0.65	0.99	0.93	0.98
Short Long Term Debt Total	0.64		0.84	0.85	0.57	0.62	1.0	0.8	0.01	-0.97	0.47	0.11	0.97	1.0	0.53	0.68	-0.32	1.0	0.84	0.99	0.93	0.57	1.0	0.54	0.82	0.48
Other Current Liab	0.78	0.84		0.95	0.73	0.74	0.87	0.87	-0.44	-0.83	0.68	0.53	0.7	0.83	0.72	0.2	-0.44	0.84	0.95	0.86	0.89	0.73	0.84	0.73	0.84	0.68
Total Current Liabilities	0.91	0.85	0.95		0.86	0.89	0.88	0.98	-0.49	-0.91	0.8	0.58	0.77	0.85	0.84	0.32	-0.57	0.85	1.0	0.89	0.85	0.86	0.86	0.85	0.96	0.81
Total Stockholder Equity	1.0	0.57	0.73	0.86		0.99	0.59	0.87	-0.77	-0.71	0.98	0.83	0.52	0.57	1.0	0.07	-0.86	0.57	0.87	0.65	0.47	1.0	0.58	1.0	0.89	0.99
Net Tangible Assets	0.99	0.62	0.74	0.89	0.99		0.64	0.92	-0.7	-0.76	0.95	0.76	0.59	0.62	0.97	0.19	-0.78	0.62	0.9	0.69	0.54	0.99	0.63	0.97	0.94	0.96
Property Plant And Equipment Net	0.66	1.0	0.87	0.88	0.59	0.64		0.82	-0.04	-0.97	0.5	0.15	0.96	1.0	0.56	0.64	-0.34	1.0	0.87	1.0	0.94	0.59	1.0	0.57	0.83	0.51
Current Deferred Revenue	0.91	0.8	0.87	0.98	0.87	0.92	0.82		-0.48	-0.89	0.81	0.57	0.76	0.8	0.84	0.38	-0.55	0.8	0.97	0.86	0.8	0.87	0.82	0.85	0.99	0.81
Net Debt	-0.73	0.01	-0.44	-0.49	-0.77	-0.7	-0.04	-0.48		0.14	-0.83	-0.99	0.11	0.01	-0.81	0.57	0.75	0.01	-0.51	-0.09	-0.02	-0.77	-0.01	-0.8	-0.46	-0.83
Retained Earnings	-0.77	-0.97	-0.83	-0.91	-0.71	-0.76	-0.97	-0.89	0.14		-0.63	-0.25	-0.96	-0.97	-0.68	-0.66	0.47	-0.97	-0.9	-0.99	-0.87	-0.71	-0.98	-0.69	-0.91	-0.64
Accounts Payable	0.97	0.47	0.68	0.8	0.98	0.95	0.5	0.81	-0.83	-0.63		0.88	0.43	0.47	0.99	-0.06	-0.91	0.47	0.81	0.56	0.38	0.98	0.49	0.99	0.81	0.99
Cash	0.8	0.11	0.53	0.58	0.83	0.76	0.15	0.57	-0.99	-0.25	0.88		0.0	0.1	0.86	-0.49	-0.78	0.11	0.6	0.2	0.13	0.83	0.12	0.86	0.55	0.88
Non Current Assets Total	0.59	0.97	0.7	0.77	0.52	0.59	0.96	0.76	0.11	-0.96	0.43	0.0		0.97	0.48	0.81	-0.32	0.97	0.76	0.96	0.84	0.52	0.97	0.49	0.79	0.44
Non Currrent Assets Other	0.63	1.0	0.83	0.85	0.57	0.62	1.0	0.8	0.01	-0.97	0.47	0.1	0.97		0.53	0.69	-0.32	1.0	0.84	0.99	0.92	0.57	1.0	0.54	0.82	0.48
Cash And Short Term Investments	0.99	0.53	0.72	0.84	1.0	0.97	0.56	0.84	-0.81	-0.68	0.99	0.86	0.48	0.53		0.01	-0.88	0.53	0.85	0.61	0.44	1.0	0.54	1.0	0.86	1.0
Common Stock Shares Outstanding	0.13	0.68	0.2	0.32	0.07	0.19	0.64	0.38	0.57	-0.66	-0.06	-0.49	0.81	0.69	0.01		0.11	0.68	0.3	0.64	0.55	0.07	0.68	0.01	0.43	-0.03
Non Current Liabilities Total	-0.82	-0.32	-0.44	-0.57	-0.86	-0.78	-0.34	-0.55	0.75	0.47	-0.91	-0.78	-0.32	-0.32	-0.88	0.11		-0.32	-0.57	-0.41	-0.1	-0.86	-0.34	-0.88	-0.58	-0.9
Capital Lease Obligations	0.64	1.0	0.84	0.85	0.57	0.62	1.0	0.8	0.01	-0.97	0.47	0.11	0.97	1.0	0.53	0.68	-0.32		0.84	0.99	0.93	0.57	1.0	0.54	0.82	0.48
Other Current Assets	0.92	0.84	0.95	1.0	0.87	0.9	0.87	0.97	-0.51	-0.9	0.81	0.6	0.76	0.84	0.85	0.3	-0.57	0.84		0.88	0.84	0.87	0.85	0.86	0.96	0.82
Other Stockholder Equity	0.71	0.99	0.86	0.89	0.65	0.69	1.0	0.86	-0.09	-0.99	0.56	0.2	0.96	0.99	0.61	0.64	-0.41	0.99	0.88		0.91	0.65	1.0	0.62	0.87	0.57
Total Liab	0.56	0.93	0.89	0.85	0.47	0.54	0.94	0.8	-0.02	-0.87	0.38	0.13	0.84	0.92	0.44	0.55	-0.1	0.93	0.84	0.91		0.47	0.92	0.45	0.78	0.38
Net Invested Capital	1.0	0.57	0.73	0.86	1.0	0.99	0.59	0.87	-0.77	-0.71	0.98	0.83	0.52	0.57	1.0	0.07	-0.86	0.57	0.87	0.65	0.47		0.58	1.0	0.89	0.99
Property Plant And Equipment Gross	0.65	1.0	0.84	0.86	0.58	0.63	1.0	0.82	-0.01	-0.98	0.49	0.12	0.97	1.0	0.54	0.68	-0.34	1.0	0.85	1.0	0.92	0.58		0.55	0.83	0.49
Total Current Assets	0.99	0.54	0.73	0.85	1.0	0.97	0.57	0.85	-0.8	-0.69	0.99	0.86	0.49	0.54	1.0	0.01	-0.88	0.54	0.86	0.62	0.45	1.0	0.55		0.86	1.0
Capital Stock	0.93	0.82	0.84	0.96	0.89	0.94	0.83	0.99	-0.46	-0.91	0.81	0.55	0.79	0.82	0.86	0.43	-0.58	0.82	0.96	0.87	0.78	0.89	0.83	0.86		0.83
Net Working Capital	0.98	0.48	0.68	0.81	0.99	0.96	0.51	0.81	-0.83	-0.64	0.99	0.88	0.44	0.48	1.0	-0.03	-0.9	0.48	0.82	0.57	0.38	0.99	0.49	1.0	0.83

Click cells to compare fundamentals

Pyxis Oncology Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Pyxis Stock Analysis

When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pyxis Current Deferred Revenue vs Cash And Short Term Investments Analysis

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Cash And Short Term Investments

Pyxis Oncology fundamental ratios Correlations

Pyxis Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Pyxis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Currrent Assets Other	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total

Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Capital Lease Obligations	- 0.97	Retained Earnings
Non Currrent Assets Other	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net